Piramal Pharma Solutions (PPS) has announced investments of USD 55 million across its sites in North America and Asia to expand its API manufacturing capabilities and capacities.
In a statement, the contract development and manufacturing organisation (CDMO) said a part of USD 55 million investment will go into new multi-purpose plants, with over 270kL of total capacity, to support the current pipeline of approximately 80 late stage programs that PPS is currently assisting its partners with at various global sites.
PPS will also expand its potency footprint at its plant in Riverview, Michigan, while augmenting early development capabilities out of Ennore in India through additions of GMP kilo labs and a pilot plant.
To serve its European biotech customers better, PPS will add early development capabilities in both, drug substance and drug product, out of its Morpeth, UK facility, it added.
Image Credit : livemint.com